Description
Function:
Medical uses
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
- Liraglutide
- DIABETICS
- BLOOD SUGAR
- obesity
- INSULIN
Production Capacity:
500000
Delivery Timeframe:
Immediate
Incoterms:
CIF - Cost, Insurance and Freight
EXW - Ex Works
FOB - Free on Board
Packaging Details:
PE bag+ foil bag+aluminum tin+carton
More about
Hybio Pharmaceutical Co., Ltd
500-1000
Employees
1
Sales volume (USD)
40%
% Export sales
Year
Established
Business type
- Industry / Manufacturer
- Business Service
Keywords
- API Peptides
- FDF
- Liraglutide
- Semaglutide
- Terlipressin
- Atosiban Ver Mais
Contact and location
- Andrew Li
- +86 xxxxxxxx
- 深圳 / | China